Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Can Fite BioPharma Charts.

Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Can Fite BioPharma Charts.

Can Fite BioPharma Ltd News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 3 March 2025 (1 week ago) • Edgar (US Regulatory)

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
Monday 3 March 2025 (1 week ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 18 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson
Tuesday 18 February 2025 (3 weeks ago) • GlobeNewswire Inc.

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 14 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25
Monday 10 February 2025 (4 weeks ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 5 February 2025 (1 month ago) • Edgar (US Regulatory)

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
Wednesday 5 February 2025 (1 month ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 27 January 2025 (1 month ago) • Edgar (US Regulatory)

US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
Monday 27 January 2025 (1 month ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 30 December 2024 (2 months ago) • Edgar (US Regulatory)

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
Monday 30 December 2024 (2 months ago) • GlobeNewswire Inc.

More Can Fite BioPharma Ltd News Articles

Kraig Biocraft Laborator... (QB)

Asia Broadband (PK)

Cann American (CE)

Intergrated Cannabis Sol... (PK)

Digital Brand Media and ... (PK)

Lightwave Logic

Northwest Biotherapeutics (QB)

Good Vibrations Shoes (PK)

Elite Pharmaceuticals (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions